Sreedevi Daggubati, MD
Hematology & Oncology · San Antonio, TXNPI 1952373656
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,905 of the $5,299 with a category attached, or 73.7%. 35 manufacturers reported payments, led by Novartis at 25.5% of the total. Reporting peaked in 2024 at $1,879 and has fallen 92.7% since, to $137 in 2025.
Across 193 payments — averaging $27.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$799
- Johnson & Johnson$379
- Myriad Genetic Laboratories, Inc.$254
- Genentech USA, Inc.$248
- AstraZeneca$193
- plus $2K from 29 others
Across 186 payments — averaging $857.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tolmar, Inc.$109K
- Seagen Inc.$17K
- TG Therapeutics, Inc.$13K
- Napo Pharmaceuticals Inc$12K
- Janssen Research & Development, LLC$7K
- AstraZeneca$3K
What the payments were for
- Food & beverage$3,90574%
- Education$3136%
- Other$1,08020%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 27 | $1,353 |
| E.r. Squibb & Sons, L.L.C. | 36 | $799 |
| Johnson & Johnson(2 entities) | 18 | $379 |
| Myriad Genetic Laboratories, Inc. | 4 | $254 |
| Genentech USA, Inc. | 16 | $248 |
| AstraZeneca(2 entities) | 4 | $193 |
| Rigel Pharmaceuticals, Inc. | 2 | $184 |
| Merck | 14 | $177 |
| Eisai Inc. | 11 | $168 |
| Pfizer | 17 | $166 |
| Amgen | 3 | $161 |
| Genmab U.S., Inc. | 1 | $125 |
| Lilly USA, LLC | 2 | $125 |
| Seagen Inc. | 3 | $125 |
| Agios Pharmaceuticals, Inc. | 1 | $122 |
| Regeneron Healthcare Solutions, Inc. | 2 | $82 |
| Sanofi | 4 | $70 |
| GSK | 3 | $67 |
| Puma Biotechnology, Inc. | 3 | $58 |
| Novocure Inc. | 1 | $56 |
| Bristol Myers Squibb | 3 | $55 |
| Gilead | 3 | $42 |
| EMD Serono, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Dendreon Pharmaceuticals LLC | 1 | $28 |
| Tempus AI, Inc | 1 | $28 |
| Array Biopharma Inc | 2 | $28 |
| Dova Pharmaceuticals | 1 | $24 |
| Bayer | 1 | $21 |
| AbbVie | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Tersera Therapeutics LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,299 in reported general payments places this provider in the 60th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 38 | $808,832 |
| ErleadaApalutamide | 31 | $460,838 |
| JakafiRuxolitinib Phosphate | 33 | $460,116 |
| CabometyxCabozantinib S-Malate | 16 | $391,254 |
| BrukinsaZanubrutinib | 25 | $378,468 |
| VerzenioAbemaciclib | 22 | $338,402 |
| InlytaAxitinib | 16 | $287,605 |
| KisqaliRibociclib Succinate | 15 | $263,904 |
| XtandiEnzalutamide | 18 | $244,384 |
| EliquisApixaban | 206 | $152,144 |
| XareltoRivaroxaban | 71 | $52,425 |
| Exemestane | 54 | $9,910 |
| Letrozole | 345 | $8,316 |
| Abiraterone Acetate | 25 | $5,543 |
| Enoxaparin Sodium | 12 | $3,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $55 | $808,83238 claims |
| Johnson & JohnsonErleada, Xarelto | $379 | $513,263102 claims |
| PfizerInlyta, Eliquis | $166 | $439,749222 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $125 | $338,59337 claims |
| NovartisKisqali | $1,353 | $263,90415 claims |
| Astellas Pharma US IncXtandi | $16 | $244,38418 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $15 | $83573 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in San Antonio
- Timothy FenskeSan Antonio$626K
- Paul ShaughnessySan Antonio$470K
- Adolfo DiazSan Antonio$463K
- Francis GilesSan Antonio$436K
- John RenshawSan Antonio$430K
- Marcela Mazo-CanolaSan Antonio$257K
- Elizabeth Bowhay-CarnesSan Antonio$204K
- Nosha FarhadfarSan Antonio$117K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.